A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma Meeting Abstract
| Authors: | Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; Maki, R. G.; Cho, J.; Biniakewitz, M.; Desir-Camille, R.; Erinjeri, J. P.; Lefkowitz, R.; Antonescu, C.; Singer, S.; Tap, W. D.; D'Angelo, S. P. |
| Abstract Title: | A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S1031 |
| Language: | English |
| ACCESSION: | WOS:001326612902342 |
| DOI: | 10.1016/j.annonc.2024.08.1812 |
| PROVIDER: | Clarivate Analytics Web of Science |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1720MO -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
